Related Experiment Video
Updated: Oct 3, 2025

Cholesterol Efflux Assay
Published on: March 6, 2012
Mechanisms of antidiabetic drugs and cholesterol efflux: A clinical perspective
Ali Ahmadi1, Mariam Bagheri Ekta2, Amirhossein Sahebkar3
1School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948567, Iran.
Abstract:
Reverse cholesterol transport (RCT) is a physiological process that reduces excess cholesterol in the body. Cholesterol efflux (CE), an important step in RCT, is mainly mediated by ATP-binding cassette transporters A1 and G1 and has a significant role in atheroprotection. Moreover, impairments in CE can lead to the development of diabetes and fatty liver disease. In this review, we summarize the possible effects of hypoglycemic agents on CE and how this might influence atherosclerosis and dyslipidemia-related pathologies. Newer antidiabetic agents could have significant potential for targeting CE and preventing or alleviating atherosclerosis, obesity, and liver steatosis, and simultaneously improving insulin secretion. However, more research is warranted to interpret the clinical relevance of these data.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hepatic Drug Clearance: Role of Transporters
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Hepatic Drug Excretion: Influencing Factors

